RVPHW
Company News
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
Reviva Pharmaceuticals will present research data on brilaroxazine's treatment effects on negative symptoms in schizophrenia patients at the CNS Summit 2025 in Boston, Massachusetts.
